Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its in-house developed bispecific antibody drug conjugate (ADC), BL-B16D1, in patients with advanced solid tumors.
Biokin Pharma, which is concentrating its efforts on the bispecific ADC sector, has previously initiated clinical studies for another bispecific ADC, the EGFR×HER3 ADC BL-B01D1, in various tumor types. This molecule was the subject of a significant licensing deal with US pharmaceutical giant Bristol-Myers Squibb, valued at USD 8.4 billion.- Flcube.com
